SEC Comment Letter 0000000000-24-005600 to CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc.
Date: May 15, 2024 · CIK: 0001729427 · Accession: 0000000000-24-005600
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279285
Letter
United States securities and exchange commission logo May 15, 2024 Christopher Downs Chief Financial Officer CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 Re:CNS Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 9, 2024 File No. 333-279285 Dear Christopher Downs: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cavas Pavri
Show Raw Text
United States securities and exchange commission logo
May 15, 2024
Christopher Downs
Chief Financial Officer
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
Re:CNS Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed May 9, 2024
File No. 333-279285
Dear Christopher Downs:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Cavas Pavri